Arcutis Biotherapeutics Inc (ARQT)

10:29 AM

Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha

10:29 AM

Nov 16, 2024

Long Term Trading Analysis for (ARQT) - Stock Traders Daily

Nov 16, 2024

Nov 15, 2024

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha

Nov 15, 2024

Nov 14, 2024

Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com

Nov 13, 2024

Nov 13, 2024

Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com UK

Nov 13, 2024

Nov 13, 2024

Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times

Nov 13, 2024

Nov 13, 2024

Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR

Nov 11, 2024

Nov 11, 2024

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance

Nov 11, 2024

Nov 08, 2024

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 08, 2024

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com

Nov 07, 2024

Nov 07, 2024

Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024

Nov 07, 2024

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlig - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance

Nov 07, 2024

Nov 06, 2024

Arcutis Biotherapeutics Reports Strong Q3 2024 Results - TipRanks

Nov 06, 2024

Nov 06, 2024

Morgan Stanley's Strategic Reduction in Arcutis Biotherapeutics Holdings - GuruFocus.com

Nov 06, 2024

Nov 06, 2024

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings: Revenue Sur - GuruFocus.com

Nov 06, 2024

Nov 06, 2024

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 06, 2024

Nov 06, 2024

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 06, 2024

Nov 06, 2024

Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Nov 06, 2024

Arcutis Q3 Revenue Soars 452% to $44.8M, ZORYVE Sales Surge Amid FDA Progress | ARQT Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

High Growth Tech Stocks In The United States To Watch - Simply Wall St

Nov 06, 2024

Nov 06, 2024

Arcutis Biotherapeutics exec sells $43,551 in stock - Investing.com India

Nov 06, 2024

Nov 06, 2024

Trend Tracker for (ARQT) - Stock Traders Daily

Nov 06, 2024

Nov 06, 2024

Arcutis biotherapeutics CMO sells $134,092 in stock - Investing.com India

Nov 06, 2024

Nov 05, 2024

Arcutis Biotherapeutics director sells $86,541 in stock - Investing.com

Nov 05, 2024

Nov 05, 2024

Arcutis biotherapeutics CMO sells $134,092 in stock By Investing.com - Investing.com UK

Nov 05, 2024

Nov 05, 2024

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024

Nov 04, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM

Nov 04, 2024

Nov 04, 2024

abrdn plc Buys 333,200 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

Nov 04, 2024

Nov 01, 2024

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 8.7% HigherHere's Why - MarketBeat

Nov 01, 2024

Oct 30, 2024

AMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

Oct 30, 2024

Oct 25, 2024

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN

Oct 25, 2024

Oct 25, 2024

Jefferies Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN

Oct 25, 2024

Oct 24, 2024

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting - StockTitan

Oct 24, 2024

Oct 24, 2024

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - The Manila Times

Oct 24, 2024

Oct 22, 2024

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 22, 2024

Oct 21, 2024

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis - Yahoo Finance

Oct 21, 2024

Oct 21, 2024

Health Canada approves Arcutis’ Zoryve foam for seborrheic dermatitis - World Pharmaceutical Frontiers

Oct 21, 2024

Oct 21, 2024

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - BioSpace

Oct 21, 2024

Oct 19, 2024

SG Americas Securities LLC Reduces Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

Oct 19, 2024

Oct 18, 2024

Behind the Bell: Arcutis Biotherapeutics - Nasdaq

Oct 18, 2024

Oct 18, 2024

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2%Here's What Happened - MarketBeat

Oct 18, 2024